24.08.2010 • News

Evonik to Expand Production Capacities in China

Demand for triacetonamine derivatives (TAA derivatives) has kept rising for several years. Evonik Industries is taking advantage of the economic opportunities afforded by this situation and is considerably expanding its production capacities for these special derivatives in China. The foundations for a new plant will be laid as early as this year.

Currently, Evonik produces the derivatives in a joint venture Evonik Tianda (Liaoyang) Chemical Additive at the Liaoyang site in northeastern China. The existing production capacities are to be moved within the Liaoyang region to the Aromatic Site (LAS), one of the country's largest petrochemical sites. Furthermore, production will be significantly increased. Full production is scheduled to commence in the fourth quarter of 2011.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.